Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Durlobactam

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Zai Lab & Pfizer Announce Collaboration on Antibacterial Drug
    Zai Lab & Pfizer Announce Collaboration on Antibacterial Drug

    21 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241121825806/en

    BUSINESSWIRE
    21 Nov 2024
    Share Share
    Zai Lab, Innoviva's SUL-DUR Approved In China For Pneumonia
    Zai Lab, Innoviva's SUL-DUR Approved In China For Pneumonia

    20 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240519020622/en

    BUSINESSWIRE
    20 May 2024
    Share Share
    Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO
    Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO

    23 May 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230523005961/en

    BUSINESSWIRE
    23 May 2023
    Share Share
    Results from Phase 3 ATTACK Trial Published in The Lancet Infectious Diseases
    Results from Phase 3 ATTACK Trial Published in The Lancet Infectious Diseases

    11 May 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230511005905/en

    BUSINESSWIRE
    11 May 2023
    Share Share
    FDA panel backs Innoviva's drug for multidrug-resistant bacterial infections
    FDA panel backs Innoviva's drug for multidrug-resistant bacterial infections

    18 Apr 2023

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-panel-backs-innovivas-drug-multidrug-resistant-bacterial-infections-2023-04-17/

    REUTERS
    18 Apr 2023
    Share Share
    Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA
    Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA

    17 Apr 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230417005846/en

    BUSINESSWIRE
    17 Apr 2023
    Share Share